Viruses are Vaccines' New Anti-Cancer Weapon
Key points
- The natural infectious power of four viruses could be the key to battling colon cancer, according to research underway at Duke University's Comprehensive Cancer Center.
- Scientists are using the viruses - vaccinia, fowlpox, adenovirus and alphavirus - to provoke the body's immune system into battling colon cancer cells.
- "Cancer has a knack for eluding the immune system and masking itself as friend instead of foe," lead researcher and cancer center director Dr.
- The most promising strategy under investigation is a one-two punch called "prime and boost.
The natural infectious power of four viruses could be the key to battling colon cancer, according to research underway at Duke University's Comprehensive Cancer Center.
Scientists are using the viruses - vaccinia, fowlpox, adenovirus and alphavirus - to provoke the body's immune system into battling colon cancer cells.
"Cancer has a knack for eluding the immune system and masking itself as friend instead of foe," lead researcher and cancer center director Dr. H. Kim Lyerly said in a prepared statement. "We've designed vaccines that more forcefully present cancer as the enemy to the patient's immune system than earlier vaccines have been able to do."
The most promising strategy under investigation is a one-two punch called "prime and boost." In it, one vaccine is used to alert or "prime" the immune system, while a second vaccine boosts the momentum of its response.
The five-year research and clinical project is being funded by a $10 million grant from the National Cancer Institute. Two biotechnology companies, Alphavax Human Vaccines Inc. and Therion Biologics, will collaborate with Duke in the research.
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsNew understanding of why anti-cancer therapy stops working at a specific stage
Researchers at the Hebrew University of Jerusalem and in California have achieved a breakthrough in understanding how and why a promising anti-cancer therapy has failed to achieve hoped-for success in killing tumor…
25 June 2013
NewsNovel monoclonal antibody inhibits tumor growth in breast cancer and angiosarcoma
A monoclonal antibody targeting a protein known as SFPR2 has been shown by researchers at the University of North Carolina to inhibit tumor growth in pre-clinical models of breast cancer and angiosarcoma. In a paper…
20 April 2013
NewsQuantifying heterogeneity in breast cancer
A variety of mutations may give rise to breast cancer, but scientists generally assume that it starts off with just a few. That's because later-stage breast cancers tend to have more mutations - they are more…
10 April 2013
